10.79  -0.153 (-1.39%)		12-12 15:55
Open: 10.964 High: 10.964 Volume: 3,703		Pre. Close: 10.9426 Low: 10.75 Market Cap: 7(M)

Short term
Mid term
Targets	6-month :	14.74	1-year :	16.14
Resists	First :	12.62	Second :	13.81
Pivot price	11.53
Supports	First :	10.68	Second :	8.88
MAs	MA(5) :	10.93	MA(20) :	11.71
	MA(100) :	10.19	MA(250) :	11.97
MACD	MACD :	-0.3	Signal :	-0.1
%K %D	K(14,3) :	10.5	D(3) :	12.8
RSI	RSI(14): 38.2
52-week	High :	17	Low :	7.13

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ PSIL ] has closed above bottom band by 19.3%. Bollinger Bands are 16.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	10.98 - 11.04	11.04 - 11.08
Low:	10.62 - 10.68	10.68 - 10.73
Close:	10.7 - 10.8	10.8 - 10.87

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.

Mon, 09 Dec 2024
(PSIL) Proactive Strategies - Stock Traders Daily

Fri, 29 Nov 2024
EMIF, PSIL: 2 ETFs with Over 20% Upside Potential, According to Analysts - TipRanks

Fri, 15 Nov 2024
No Trippin’: Trump Trade Pushes PSIL, VCAR Higher - etf.com

Fri, 15 Nov 2024
5 Best-Performing Sector ETFs Midway in Q4 - November 15, 2024 - Zacks Investment Research

Thu, 17 Oct 2024
DRUG Enhances Buzz for Psilocybin, Psychedelic ETFs - etf.com

Thu, 17 Oct 2024
DRUG Enhances Buzz for Psilocybin, Psychedelic ETFs - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.